Pharmaceutical

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Dermavant will include these findings in an upcoming supplemental new drug application (sNDA) submission, which is expected in Q1 2024.

Jan 13, 2024 - 18:00
Dermavant maps out atopic dermatitis filing after positive Phase III data 
Dermavant will include these findings in an upcoming supplemental new drug application (sNDA) submission, which is expected in Q1 2024.
Read the original article

Tags:

Previous Article

Santhera’s Agamree becomes first approved treatment in UK for all DMD patients

Next Article

Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: GE HealthCare CEO named chair of AdvaMed as device lobby forms new imaging division

STAT+: GE HealthCare CEO named chair of AdvaMed as devi...

Dec 11, 2023

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb acquires Karuna Therapeutics for $...

Mar 20, 2024

STAT+: Merck, Johnson & Johnson CEOs agree to testify in Congress on high drug prices, avoiding Bernie Sanders’ subpoena

STAT+: Merck, Johnson & Johnson CEOs agree to testify i...

Jan 26, 2024